Legemiddelfirmaet GSK søker Key Account Manager
GSK er et globalt forskningsdrevet biofarmasøytisk selskap. GSKs mål er å forene vitenskap, teknologi og talent, slik at vi sammen kan være i forkant av sykdomsutviklingen. Vi tilbyr et bredt spekter av vaksiner og legemidler, både til bruk innen spesialist- og primærhelsetjenesten. Vår forskning og utvikling er fokusert på immunforsvaret, genetikk og avansert teknologi innen fire hovedområder; infeksjonssykdommer, hiv, onkologi og lungesykdommer. I GSK Norge er vi ca. 60 personer, og vi holder til på Lysaker. Vi jobber med alt fra medisinske prosjekter til markedstilgang/helseøkonomi, markedsføring, salg og ulike støttefunksjoner - alt for å sørge for at norske pasienter og samfunnet kan ta i bruk nye medisiner og vaksiner.
Bayer is seeking Head of Technology Development
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result, we are investing heavily in production and R&D in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 50-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
QA Direktør søkes til IFE Divisjon Radiofarmasi
Divisjon Radiofarmasi er en del av IFE (Institutt for Energiteknikk) og holder til på Kjeller. Divisjonen har en verdensledende produksjonsvirksomhet innen radioaktive legemidler og skal ved årsskiftet 2022/23 skilles ut og etableres som et eget AS. Med norske og multinasjonale samarbeidspartnere utvikles, produseres og distribueres banebrytende legemidler for kreftpasienter over hele verden. Divisjonen er i dag om lag 150 medarbeidere i virksomheten, med en omsetning på ca. 360 mill. kr
NorthSea Therapeutics seeking Project Manager
NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. NST licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS, who developed Lovaza® (US brand, branded Omacor® in Europe), a blockbuster cardiovascular drug. Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA-1024 is in phase 1 to be developed for dyslipidemia, and SEFA-6179, entered phase 1 in December 2021, is being developed for the orphan indication IFALD, (Intestinal Failure Associated Liver Disease). NST is headquartered in the Netherlands with a presence in Norway and the US and is supported by Ysios Capital, Forbion Growth, Hercules Capital, Forbion Ventures, Novo Seeds, BGV, NSV, venBio Partners and Sofinnova investments.
GSK søker Nasjonal Salgssjef
GSK er et globalt forskningsdrevet biofarmasøytisk selskap. GSKs mål er å forene vitenskap, teknologi og talent, slik at vi sammen kan være i forkant av sykdomsutviklingen. Vi tilbyr et bredt spekter av vaksiner og legemidler, både til bruk innen spesialist- og primærhelsetjenesten. Vår forskning og utvikling er fokusert på immunforsvaret, genetikk og avansert teknologi innen fire hovedområder; infeksjonssykdommer, hiv, onkologi og lungesykdommer. I GSK Norge er vi ca. 60 personer, og vi holder til på Lysaker. Vi jobber med alt fra medisinske prosjekter til markedstilgang/helseøkonomi, markedsføring, salg og ulike støttefunksjoner - alt for å sørge for at norske pasienter og samfunnet kan ta i bruk nye medisiner og vaksiner.
FMGC – legemidler – business development
Santen er et av verdens ledende foretak innen øyeforskning. Santen ble etablert i Japan i 1890 og er i dag en av verdens største produsenter av legemidler innen behandling av øyesykdommer og forbedring av menneskers syn. Vi er overbevist om at bedre syn også gir en høyere livskvalitet. Derfor har vi i Santen satt øyet og synsevnen i sentrum for hele vår virksomhet som legemiddelfirma. Santens virksomhet består av reseptbelagte øyelegemidler, reseptfrie øyebehandlinger og medisinske hjelpemidler samt kosttilskudd for øyehelse. I Europa er vi ledende innen behandling av grønn stær og tørt øye-sykdom – områder der porteføljen vår dekker alle stadier og typer av sykdommer. Vi er også i ferd med å utvide sortimentet når det gjelder øyeinfeksjoner, allergier og utstyr for synskorrigering og kirurgi.
Agiana Pharma is looking for Director Regulatory Affairs & Quality Assurance
There is a great unmet need for a new anti-arrhythmic drug in patients with heart failure. Agiana Pharma, a Norwegian based pharmaceutical company founded in 2021, is developing the first new class of anti-arrhythmic therapy in 50 years. Our lead candidate AGP 100 is targeting a large patient population with a great unmet need. AGP 100 is protected by a strong IP portfolio and supported by extensive pre-clinical and clinical phase I data, with evidence of an excellent tolerability and safety profile. With a strong Board of Directors and Scientific Advisory Board, we are now heading for Phase IIa proof of concept study.
Agiana Pharma is looking for Director Clinical Research
There is a great unmet need for a new anti-arrhythmic drug in patients with heart failure. Agiana Pharma, a Norwegian based pharmaceutical company founded in 2021, is developing the first new class of anti-arrhythmic therapy in 50 years. Our lead candidate AGP 100 is targeting a large patient population with a great unmet need. AGP 100 is protected by a strong IP portfolio and supported by extensive pre-clinical and clinical phase I data, with evidence of an excellent tolerability and safety profile. With a strong Board of Directors and Scientific Advisory Board, we are now heading for Phase IIa proof of concept study.
Development Manager Radiopharmaceuticals
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change. For more information see www.bayer.no
Radiopharmaceuticals Development Platform Lead
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change. For more information see www.bayer.no
Scientist Radiopharmaceuticals
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
Vice President Research & Development
Amicoat AS is a Norwegian biotechnology company that discovers, develops, and commercializes novel antimicrobial science with broad applications across diverse industries. Our current focus is on medical equipment, and we are also exploring utilization of our technology in other industries. With our origins above the Arctic Circle in the city of Tromsø in Northern Norway, we aspire to be a leading company in the antimicrobial coating industry, providing our clients with tailored antimicrobial coating solutions. Our primary product, AMC-109, offers a reliable and environmentally safe antimicrobial solution addressing needs across a wide range of industries. AMC-109 is backed by extensive data demonstrating efficacy and safety, and inducing antimicrobial activity with minimal environmental impact. Efficacy has also been demonstrated with viruses and fungi.
Brand Manager – Boehringer Ingelheim
Hos Boehringer Ingelheim skaper vi verdi gjennom innovasjon med ett klart mål: å forbedre livene til pasientene. Vi forsker på og utvikler banebrytende og innovative løsninger innen områder med uoppfylt medisinsk behov for både mennesker og dyr. Som et familieeid selskap har vi et langsiktig fokus. Vi kan oppsummere målene og ideene i Boehringer Ingelheim med én setning: Verdi gjennom nyskapning. Vi er over 50.000 ansatte globalt og har en kultur som preges av mangfold, samarbeid og inkluderende arbeidsmiljø. Vi drives av kontinuerlig læring og utvikling for alle ansatte, fordi din vekst er vår vekst. I Norge holder vi til i Asker og sysselsetter 65 kompetente medarbeidere.
Product Design and Development Lead
We are a stealth early stage biotech with multiple locations, including Oslo, Basel, and soon Cambridge (USA) - the name will change shortly! Our mission is to develop therapeutics that extend patients' lives and also improve their quality of life. We specialize in developing targeted radioligand therapeutics and we are growing our new company with roots in the Oslo ecosystem of radiobiology, and founders with a track record of developing new therapies. We are backed by international venture capital groups with deep scientific roots who understand what it takes to develop and scale a technology to deliver new therapies.
NorthSea Therapeutics is seeking CMC Manager
NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. NST licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS, who developed Lovaza® (US brand, branded Omacor® in Europe), a blockbuster cardiovascular drug. Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA-1024 is in phase 1 to be developed for dyslipidemia, and SEFA-6179, entered phase 1 in December 2021, is being developed for the orphan indication IFALD, (Intestinal Failure Associated Liver Disease). NST is headquartered in the Netherlands with a presence in Norway and the US and is supported by Ysios Capital, Forbion Growth, Hercules Capital, Forbion Ventures, Novo Seeds, BGV, NSV, venBio Partners and Sofinnova investments. Find out more about us online at: www.northseatherapeutics.com
Boehringer Ingelheim søker Medical Manager
Hos Boehringer Ingelheim skaper vi verdi gjennom innovasjon med ett klart mål: å forbedre livene til pasientene. Vi forsker på og utvikler banebrytende og innovative løsninger innen områder med uoppfylt medisinsk behov for både mennesker og dyr. Som et familieeid selskap har vi et langsiktig fokus. Vi kan oppsummere målene og ideene i Boehringer Ingelheim med én setning: Verdi gjennom nyskapning. Vi er over 50.000 ansatte globalt og har en kultur som preges av mangfold, samarbeid og inkluderende arbeidsmiljø. Vi drives av kontinuerlig læring og utvikling for alle ansatte, fordi din vekst er vår vekst.
Astellas søker Key Account Manager Oncology
At Astellas we can offer an inspiring place to work and a chance to make your mark in doing good for others. Our expertise, science and technology make us a pharma company, our open and progressive culture is what makes us Astellas. It’s a culture of doing good for others and contributing to a sustainable society. Delivering meaningful differences for patients is our driving force. We all have a significant opportunity to make that difference, working locally in the areas we know best, whilst drawing inspiration from the different insights and expertise we have access to globally and from our innovative, external partners. Our ethos is underpinned by the Astellas Way, comprising five core values: patient focus; ownership; results; openness and integrity. We are proud to offer an inclusive and respectful working environment that fosters collaboration and ownership. Our aspiration is to bring the best minds together and provide world-leading tools and resources in a unique structure that fosters real agility and entrepreneurial spirit.
Bayer is looking for Preclinical Imaging Scientist
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. As one of the world’s leading innovation companies we are a trendsetter in research intensive areas. Bayer's products and services are designed to improve quality of life. In 2014 Bayer acquired the Norwegian biotech company Algeta and further strengthened our position within innovative cancer research and development. As a result we are investing heavily in production and Research & Development in Norway and increasing our ambition to provide patients with innovative and qualitative treatment. The integration of Algeta is a unique chapter in Bayer’s 57-year long Norwegian history and our greatest pride. Bayer has 160 employees in Norway and is located at Lysaker in new and attractive offices and laboratories. At Bayer you have the opportunity to be part of a culture where we value passion to innovate and give our employees the power to change.
Janssen søker Marketing Manager
Menneskene som arbeider hos Janssen i Norden er alle en viktig del av et av verdens ledende forskningsbaserte farmasøytiske selskaper. Vi er levende opptatt av å forbedre helsevesenet og sørge for økt livskvalitet for mennesker i hele verden. Vi har et godt nettverk med mer enn 280 kolleger innenfor Janssen Nordic-organisasjonen i Danmark, Finland, Island, Norge og Sverige. Vi samarbeider svært godt både i lokale team og på tvers av landegrensene – enten gjennom direkte kontakt eller ved bruk av det aller siste innen digital teknologi. Samtidig samarbeider vi i et globalt nettverk som teller mer enn 40 000 Janssen-kolleger som jobber hardt for å behandle, kurere, stoppe og forhindre noen av de mest ødeleggende og komplekse sykdommene i vår tid - fra autoimmune sykdommer, hematologi, onkologi, HIV, psykiske lidelser, hjertesykdom og diabetes.
Norwegian Bladder Cancer Company with international success is looking for a Quality and Compliance Manager
Photocure, The Bladder Cancer Company: Our story began in 1997 at our headquarters in Oslo, Norway. Since then, our expertise and vision have contributed to becoming an international specialist in the field of bladder cancer. Our unique technology, which makes cancer cells glow bright pink, has helped patients worldwide. Working with our partners, we are committed to transformative solutions that can improve the lives of bladder cancer patients. For more information, please visit us at www.photocure.com
Nykode Therapeutics is looking for a Senior Process Development Scientist
Our company was founded in 2007 and has since then, become one of the world’s most exciting Biotech companies, rapidly growing. Today we are counting more than 60 amazing employees within medical and development teams, manufacturing, bioinformatics, and research teamsWe use the Vaccibody technology to generate therapeutics with best-in-class potential to treat cancers with a high unmet medical need. Furthermore, we also focus our research on infectious diseases and immune tolerance. We closely collaborate with Roche and Nektar Therapeutics. And we are proud to have entered into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccines.
Nykode Therapeutics is looking for a Senior Formulation Development Scientist
Our company was founded in 2007 and has since then, become one of the world’s most exciting Biotech companies, rapidly growing. Today we are counting more than 60 amazing employees within medical and development teams, manufacturing, bioinformatics, and research teams. We use the Vaccibody technology to generate therapeutics with best-in-class potential to treat cancers with a high unmet medical need. Furthermore, we also focus our research on infectious diseases and immune tolerance. We closely collaborate with Roche and Nektar Therapeutics. And we are proud to have entered into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, to develop individualized neoantigen cancer vaccines.
Boehringer Ingelheim søker Market Access Manager
Hos Boehringer Ingelheim skaper vi verdi gjennom innovasjon med ett klart mål: å forbedre livene til pasientene. Vi forsker på og utvikler banebrytende og innovative løsninger innen områder med uoppfylt medisinsk behov for både mennesker og dyr. Som et familieeid selskap har vi et langsiktig fokus. Vi kan oppsummere målene og ideene i Boehringer Ingelheim med én setning: Verdi gjennom nyskapning. Vi er 52 000 ansatte globalt som fremmer en mangfoldig, samarbeidende og inkluderende kultur. Vi tror at hvis vi har talentfulle og ambisiøse mennesker som brenner for innovasjon, er det ingen grense for hva vi kan oppnå. Vi drives av kontinuerlig læring og utvikling for alle ansatte, fordi din vekst er vår vekst. Vårt norske kontor ligger sentralt i Asker og vi er 70 ansatte.
Quality Assurance Specialist / Qualified Person
Bayer er en internasjonal virksomhet med kjernekompetanse innen helse, ernæring og høyteknologiske materialer. Konsernet består av et holdingselskap, Bayer AG, som står for den strategiske ledelsen, og 3 delkonsern som har ansvar for forretningsområdene Pharmaceuticals, Consumer Health og CropScience. Målet med våre produkter og tjenester er å forbedre menneskers og dyrs livskvalitet. Våre verdier skaper vi gjennom innovasjon, vekst og økt lønnsomhet. Bayerkonsernet har forpliktet seg til å følge prinsippene om en bæredyktig utvikling, også i sin rolle som sosial og etisk ansvarlig selskap. Økonomisk, miljømessig og sosial ansvarlighet vektes derfor like høyt i vår virksomhet. I 2014 kjøpte Bayer AS opp den norske biotech-suksessen Algeta ASA, og vi styrket med dette vår rolle innen fremtidsrettet onkologisk forskning og utvikling. Algeta-teamet er nå fullt integrert i Bayer og jobber nå sammen for å utvikle virksomheten til dens fulle potensial. Samtidig øker vi våre ambisjoner om å gi pasientene innovative og kvalitative behandlingsmuligheter. For Bayer er integreringen av Algeta et unikt kapittel i vår 57-årige norske historie og noe vi er svært stolte av.